Expanded Access Programm BIBW 2992 for NSCLC Last Line Treatment.

Trial Profile

Expanded Access Programm BIBW 2992 for NSCLC Last Line Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Nov 2016 Status changed from recruiting to completed.
    • 02 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top